Scientific Hepatectomy for Hepatocellular Carcinoma

被引:0
作者
Gu, Jin [1 ,2 ]
Liang, Bin-yong [1 ]
Zhang, Er-lei [1 ]
Zhang, Zun-yi [1 ]
Chen, Xiao-ping [1 ]
Huang, Zhi-yong [1 ]
机构
[1] Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Hepat Surg Ctr, Wuhan 430030, Peoples R China
[2] Zhejiang Univ, Affiliated Hosp 2, Sch Med, Dept Hepatobiliary & Pancreat Surg, Hangzhou 310009, Peoples R China
关键词
hepatocellular carcinoma; scientific hepatectomy; liver cirrhosis; vascular invasion; immunotherapy; VENOUS-PRESSURE GRADIENT; HUMAN-LIVER-REGENERATION; MAJOR HEPATIC RESECTION; MICROVASCULAR INVASION; PORTAL-HYPERTENSION; ANATOMIC RESECTION; HISTOLOGICAL SUBCLASSIFICATION; NONANATOMICAL RESECTION; INTRAHEPATIC RECURRENCE; CIRRHOTIC-PATIENTS;
D O I
10.1007/s11596-023-2761-2
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
With advances in imaging technology and surgical instruments, hepatectomy can be perfectly performed with technical precision for hepatocellular carcinoma (HCC). However, the 5-year tumor recurrence rates remain greater than 70%. Thus, the strategy for hepatectomy needs to be reappraised based on insights of scientific advances. Scientific evidence has suggested that the main causes of recurrence after hepatectomy for HCC are mainly related to underlying cirrhosis and the vascular spread of tumor cells that basically cannot be eradicated by hepatectomy. Liver transplantation and systemic therapy could be the solution to prevent postoperative recurrence in this regard. Therefore, determining the severity of liver cirrhosis for choosing the appropriate surgical modality, such as liver transplantation or hepatectomy, for HCC and integrating newly emerging immune-related adjuvant and/or neoadjuvant therapy into the strategy of hepatectomy for HCC have become new aspects of exploration to optimize the strategy of hepatectomy. In this new area, hepatectomy for HCC has evolved from a pure technical concept emphasizing anatomic resection into a scientific concept embracing technical considerations and scientific advances in underlying liver cirrhosis, vascular invasion, and systemic therapy. By introducing the concept of scientific hepatectomy, the indications, timing, and surgical techniques of hepatectomy will be further scientifically optimized for individual patients, and recurrence rates will be decreased and long-term survival will be further prolonged.
引用
收藏
页码:897 / 907
页数:11
相关论文
共 95 条
  • [1] Resection or Transplantation for Early Hepatocellular Carcinoma in a Cirrhotic Liver Does Size Define the Best Oncological Strategy?
    Adam, Rene
    Bhangui, Prashant
    Vibert, Eric
    Azoulay, Daniel
    Pelletier, Gilles
    Duclos-Vallee, Jean-Charles
    Samuel, Didier
    Guettier, Catherine
    Castaing, Denis
    [J]. ANNALS OF SURGERY, 2012, 256 (06) : 883 - 891
  • [2] [Anonymous], 2000, HPB, V2, P333, DOI [10.1080/136518202760378489, DOI 10.1016/S1365-182X(17)30755-4]
  • [3] CHRONIC HEPATITIS - AN UPDATE ON TERMINOLOGY AND REPORTING
    BATTS, KP
    LUDWIG, J
    [J]. AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 1995, 19 (12) : 1409 - 1417
  • [4] An algorithm for the grading of activity in chronic hepatitis C
    Bedossa, P
    Poynard, T
    [J]. HEPATOLOGY, 1996, 24 (02) : 289 - 293
  • [5] Portal Hypertension and the Outcome of Surgery for Hepatocellular Carcinoma in Compensated Cirrhosis: A Systematic Review and Meta-analysis
    Berzigotti, Annalisa
    Reig, Maria
    Abraldes, Juan G.
    Bosch, Jaime
    Bruix, Jordi
    [J]. HEPATOLOGY, 2015, 61 (02) : 526 - 536
  • [6] Hepatic venous pressure gradient in the assessment of portal hypertension before liver resection in patients with cirrhosis
    Boleslawski, E.
    Petrovai, G.
    Truant, S.
    Dharancy, S.
    Duhamel, A.
    Salleron, J.
    Deltenre, P.
    Lebuffe, G.
    Mathurin, P.
    Pruvot, F. R.
    [J]. BRITISH JOURNAL OF SURGERY, 2012, 99 (06) : 855 - 863
  • [7] Management of hepatoceullular carcinoma
    Bruix, J
    Sherman, M
    [J]. HEPATOLOGY, 2005, 42 (05) : 1208 - 1236
  • [8] Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial
    Bruix, Jordi
    Takayama, Tadatoshi
    Mazzaferro, Vincenzo
    Chau, Gar-Yang
    Yang, Jiamei
    Kudo, Masatoshi
    Cai, Jianqiang
    Poon, Ronnie T.
    Han, Kwang-Hyub
    Tak, Won Young
    Lee, Han Chu
    Song, Tianqiang
    Roayaie, Sasan
    Bolondi, Luigi
    Lee, Kwan Sik
    Makuuchi, Masatoshi
    Souza, Fabricio
    Le Berre, Marie-Aude
    Meinhardt, Gerold
    Llovet, Josep M.
    [J]. LANCET ONCOLOGY, 2015, 16 (13) : 1344 - 1354
  • [9] Risk factors and management for early and late intrahepatic recurrence of solitary hepatocellular carcinoma after curative resection
    Cheng, Zhangjun
    Yang, Pinghua
    Qu, Shuping
    Zhou, Jiahua
    Yang, Jue
    Yang, Xinwei
    Xia, Yong
    Li, Jun
    Wang, Kui
    Yan, Zhenlin
    Wu, Dong
    Zhang, Baohua
    Hueser, Norbert
    Shen, Feng
    [J]. HPB, 2015, 17 (05) : 422 - 427
  • [10] Medical progress: Strategies for safer liver surgery and partial liver transplantation
    Clavien, Pierre-Alain
    Petrowsky, Henrik
    DeOliveira, Michelle L.
    Graf, Rolf
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2007, 356 (15) : 1545 - 1559